Supernus to Participate in Upcoming September Investor Conferences

On September 2, 2021 Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, reported that the Company’s management will participate and host investor meetings in the following upcoming September 2021 virtual investor conferences (Press release, Supernus, SEP 2, 2021, View Source [SID1234587163]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 16th Annual BioPharma Virtual Conference
Date: Thursday, September 9, 2021
Participation Type: One-on-one meetings

Wells Fargo 2021 Virtual Healthcare Conference
Date: Friday, September 10, 2021
Participation Type: Presentation
Presentation Time: 9:20 a.m. ET

Morgan Stanley 19th Annual Global Healthcare Conference
Date: Wednesday, September 15, 2021
Participation Type: Fireside Chat
Presentation Time: 11:45 a.m. ET

A live webcast of the events can be accessed by visiting Events & Presentations in the Investor Relations section on the Company’s website at www.supernus.com. An archived replay of each webcast will be available for 60 days on the Company’s website after the respective conference.

Jounce Therapeutics to Present at Upcoming Investor Conferences in September

On September 2, 2021 Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, reported that company management will participate at several upcoming investor conferences in September (Press release, Jounce Therapeutics, SEP 2, 2021, View Source [SID1234587179]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2021 Wells Fargo Virtual Healthcare Conference: Fireside chat on Friday September 10, 2021 at 8:00 a.m. ET.
H.C. Wainwright 23rd Annual Global Investment Conference: Presentation will be available on-demand during the conference, starting on Monday, September 13, 2021 at 7:00 a.m. ET.
Baird’s 2021 Global Healthcare Conference: Presentation on Wednesday, September 15, 2021 at 12:15 p.m. ET.
2021 Cantor Fitzgerald Virtual Global Healthcare Conference: Presentation on Wednesday, September 29, 2021 at 4:00 p.m. ET.
A webcast of the presentations will be available by visiting "Events and Presentations" in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcasts will be archived for 30 days following the presentation.

Repare Therapeutics to Participate at the 19th Annual Morgan Stanley Virtual Global Healthcare Conference

On September 2, 2021 Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, reported that members of its senior management team will participate in a fireside chat at the 19th Annual Morgan Stanley Virtual Global Healthcare Conference on Thursday, September 9 at 2:45 p.m. Eastern Time (Press release, Repare Therapeutics, SEP 2, 2021, View Source [SID1234587198]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat can be accessed in the Investor section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 30 days.

Apex Friendship Graduate Receives Inaugural $50,000 Scholarship from Almac Group

On September 2, 2021 Almac Group reported that Khadeeja Ali Syeda, a 2021 graduate of Apex Friendship High School, has been selected as the recipient of the inaugural Almac Group Scholarship, and will receive $50,000 over the next four years (Press release, Almac, SEP 2, 2021, View Source [SID1234587217]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

After an independent review by Triangle Community Foundation’s seasoned scholarship committee, Khadeeja was named this year’s recipient due to her impressive academic performance and involvement in the community, interest in pursuing a STEM career, and powerful personal statement. She will attend North Carolina State University and will receive, in addition to tuition assistance, mentorship opportunities and unique exposure to Almac Group’s career opportunities in the global pharmaceutical and biotech industry.

Commented Donna Christopher, Global VP of Operations, Almac Clinical Services, "Almac and the McClay Foundation support students in overcoming barriers to education across the world, and I am so pleased that we have expanded our reach to create opportunity here in the Triangle region. On behalf of Almac, we are excited to offer the inaugural Almac Group Scholarship to Khadeeja Ali Syeda, whom we had the recent pleasure of meeting at our facility in Durham prior to her first day at North Carolina State University. She is an impressive student who is well-prepared to succeed, and we look forward to continuing to forge a relationship with her as we provide support to help chart her success during her college career and beyond."

Commented Khadeeja Ali Syeda, ""I would like to thank Almac for their generosity. This scholarship will alleviate much of the financial burden I had due to the cost of my education, and will make it easier for me to pursue my goals. I am honored to have been the recipient of this award, and I am excited for the opportunities it will open up for me in the future."

The Almac Group Scholarship Fund was established in Spring2021 in partnership with Triangle Community Foundation to support a substantial, multi-year scholarship award for a selected first-year college student in the Triangle region. Triangle Community Foundation is responsible for scholarship administration and independent evaluation of scholarship candidates, and the McClay Foundation, which wholly owns the Almac Group, is the sole financier of the Fund and its subsequent awards, including this year’s award.

Commented Julia Da Silva, Scholarships Officer at Triangle Community Foundation, "We’re thrilled to be able to partner with Almac Group to support Khadeeja through her college journey and see her join our community of scholars. We can’t wait to see the positive impact she will have on her community and the amazing things she will do with the degree she has chosen to pursue."

The McClay Foundation was established by the late Sir Allen McClay, one of Northern Ireland’s most distinguished entrepreneurs and philanthropists and founder of Almac Group, with the vision to "make a meaningful improvement and advance human health," through the contributions of Almac Group’s innovative family of companies and support to a wide range of global charitable organizations.

Alligator is exploring financing alternatives to support phase II studies for Mitazalimab, phase II preparations for ATOR-1017 as well as the development of other pipeline

On September 2, 2021 Alligator Bioscience AB ("Alligator" or the "Company") reported that the Company, in order to enable further progress, will begin evaluating potential financing alternatives, which may include issuance of equity (Press release, Alligator Bioscience, SEP 2, 2021, View Source [SID1234587144]). Alligator’s board has appointed financial advisors and the Company has received support from certain of the Company’s largest shareholders for continued funding of the Company.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To give Alligator’s new and experienced management team the right opportunities to develop the Company, the Board’s current assessment is that working capital will need to be strengthened in order to enable phase II studies for Mitazalimab, phase II preparations for ATOR-1017 as well as the development of other pipeline candidates and general corporate purposes. The Company will now continue dialogues with relevant stakeholders, evaluate its available funding alternatives, and revert to the market with more information in due course.

This information is such information as Alligator Bioscience AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 12:00 p.m. CEST on September 2, 2021.